CATEGORIES
- HGH & Peptide
- Testosterone Series
- Nandrolone Series
- Boldenon Series
- Trenbolone Series
- DHEA Series
- Oral Steroids Series
- Antiestrogen Series
- Estrogen series
- Epinephrine & Thyroxine
- Nootropic API
- SARMs
- Finished Steroid
- Molecularly targeted cancer API
Latest news
- The dosage of HGH
- The History of HGH
- What is HGH?
- High Growth hormone
- How to use HGH?
- The Copy of Growth Hormone
Contact us
- ADD: HongKong
- TEL: skype: sophia.koffeepharm
- FAX: sophia@koffeepharm.com
- E-mail: sophia@koffeepharm.com
GFT505
- Product description: supply good quality GFT505 CAS: 824932-88-9
PRODUCT INTRODUCTION
GFT505(ELAFIBRANOR)
|
Product Name: |
GFT505 |
Synonyms: |
GFT505;elafibranor |
|
CAS: |
824932-88-9 |
|
MF: |
|
|
MW: |
0 |
|
EINECS: |
0 |
|
Mol File: |
Mol File |
Description
Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α (PPAR-α) and peroxisome proliferator-activated receptor-δ (PPAR-δ) with EC50 values of 45 and 175 nM, respectively.
In Vitro
GFT505 is being developed as a dual PPAR-α/PPAR-δ agonist for the treatment of T2DM and non-alcoholic fatty liver disease. GFT505 has an active metabolite, GFT1007, and both have potent agonist activity for PPAR-α and to a lesser extent for PPAR-δ
In Vivo
GFT505 improves insulin sensitivity and early studies indicate it may be useful in non-alcoholic fatty liver disease which is being tested in a Phase IIb study[1]. Elafibranor is well tolerated and does not cause weight gain or cardiac events, but does produce a mild, reversible increase in serum creatinine. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation[2]. GFT505 treatment improves glucose control and plasma lipids in diabetic db/db mice. A significant dose-dependent reduction of hepatic expression of the key gluconeogenic enzymes glucose 6-phosphatase (G6Pase), PEPCK, and fructose 1,6-bisphosphatase 1 (FBP1) is observed with GFT505. GFT505 does not induce cardiac adverse effects of PPARγ-activating agonists in monkeys